Literature DB >> 21176721

Contribution of 1173C > T polymorphism in the VKORC1 gene to warfarin dose requirements in Han Chinese patients receiving anticoagulation.

J Yang1, C Huang, Z Shen, L Miao.   

Abstract

OBJECTIVE: The objective was to assess 1173C > T polymorphism of the VKORC1 gene and its contribution to warfarin dose requirements in Han Chinese patients.
METHODS: Blood samples were collected from 178 patients with stable warfarin dose requirements and an international normalized ratio (INR) of the prothrombin time within the target range (1.5 - 3.0). Polymorphisms for VKORC1 (1173C > T), CYP2C9, venous INR, and plasma concentration and unbound concentration of warfarin were analyzed.
RESULTS: VKORC1 (1173C > T) genotyping showed that 154 patients were homozygous TT, 23 were heterozygous CT, and one was homozygous for the CC genotype. Patients with the VKORC1 (1173CC + CT) genotype required a significantly higher warfarin dose (3.33 ± 1.04 mg/day) than those with 1173TT (1.81 ± 0.63 mg/day; p < 0.001). The multiple linear regression model for warfarin dose indicated significant contributions from the VKORC1 (1173C > T) genotype (r2 = 0.355; p < 0.001), and age, body weight, and CYP2C9 and VKORC1 genotype together (r2 = 0.513; p < 0.001). The two SNPs (-1639 and 1173) were found to be in very strong linkage disequilibrium with estimated D' = 0.96 (95%CI (0.83 - 0.99)).
CONCLUSION: The VKORC1 (1173C > T) polymorphism might be very important, and its contribution can be equally explained by the VKORC1(-1639 G > A) polymorphism for warfarin dose requirements in Han Chinese patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21176721     DOI: 10.5414/cpp49023

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  7 in total

1.  The prevalence of VKORC1 1639 G>A and CYP2C9*2*3 genotypes in patients that requiring anticoagulant therapy in Turkish population.

Authors:  Coskun Silan; Omer Tamer Dogan; Fatma Silan; Fatma Mutlu Kukulguven; Halil Fatih Asgun; Semra Ozdemir; Ahmet Uludag; Sinem Atik; Buket Gungor; Seçil Akdur; Hakki Engin Aksulu; Oztürk Ozdemir
Journal:  Mol Biol Rep       Date:  2012-10-14       Impact factor: 2.316

Review 2.  The pharmacogenetics of the response to warfarin in Chinese.

Authors:  May P S Lam; Bernard M Y Cheung
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

Review 3.  Effect of genetic variants, especially CYP2C9 and VKORC1, on the pharmacology of warfarin.

Authors:  Erik Fung; Nikolaos A Patsopoulos; Steven M Belknap; Daniel J O'Rourke; John F Robb; Jeffrey L Anderson; Nicholas W Shworak; Jason H Moore
Journal:  Semin Thromb Hemost       Date:  2012-10-06       Impact factor: 4.180

4.  Effects of VKORC1 Genetic Polymorphisms on Warfarin Maintenance Dose Requirement in a Chinese Han Population.

Authors:  Xiaojuan Yan; Feng Yang; Hanyun Zhou; Hongshen Zhang; Jianfei Liu; Kezhong Ma; Yi Li; Jun Zhu; Jianqiang Ding
Journal:  Med Sci Monit       Date:  2015-11-19

Review 5.  Impact of CYP2C9, VKORC1 and CYP4F2 genetic polymorphisms on maintenance warfarin dosage in Han-Chinese patients: A systematic review and meta-analysis.

Authors:  Jinhua Zhang; Zhijie Chen; Chunmei Chen
Journal:  Meta Gene       Date:  2016-07-05

6.  Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation.

Authors:  Jiao Li; Wenlong Yang; Zhonghui Xie; Kun Yu; Yuhua Chen; Kaijun Cui
Journal:  BMC Cardiovasc Disord       Date:  2018-05-18       Impact factor: 2.298

7.  DBCSMOTE: a clustering-based oversampling technique for data-imbalanced warfarin dose prediction.

Authors:  Yanyun Tao; Yuzhen Zhang; Bin Jiang
Journal:  BMC Med Genomics       Date:  2020-10-22       Impact factor: 3.063

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.